<?xml version="1.0" encoding="UTF-8"?>
<ref id="B133">
 <label>133.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Group</surname>
    <given-names>HTC</given-names>
   </name>
  </person-group>. 
  <article-title>HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment</article-title>. 
  <source>Eur Heart J</source>. (
  <year>2013</year>) 
  <volume>34</volume>:
  <fpage>1279</fpage>â€“
  <lpage>91</lpage>. 
  <pub-id pub-id-type="doi">10.1093/eurheartj/eht055</pub-id>
  <?supplied-pmid 23444397?>
  <pub-id pub-id-type="pmid">23444397</pub-id>
 </mixed-citation>
</ref>
